Abstract:
The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers comprising amino acids tyrosine (Y), phenylalanine (F), alanine (A), and lysine (K). The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.
Abstract:
An ultrasound system and method provide a workflow to acquire 3D images of the fetal heart gated by a synthetic heart gating signal. An ROI is defined in an ultrasound image which delineates the fetal heart. The ultrasound system is controlled to automatically estimate the fetal heart rate from echo signals received from the ROI. When the system has acquired a stable synthetic heart rate signal, an indication thereof is given to the user and the user then commands the system to acquire 3D fetal heart images for a number of fetal heart cycles which are gated using the synthetic heart rate signal.
Abstract:
A barrier movement operator controls movement of a movable barrier. The barrier movement operator includes a head unit, including a chassis, for commanding the movable barrier to perform movable barrier functions. A plurality of closely mounted light emitting elements are fixedly mounted onto the head unit. A heat sink is in thermal communication with the set of light emitting elements and with the chassis of the barrier movement operator to dissipate thermal energy from the set of light emitting elements. A controller is utilized for controlling the head unit to provide power to the set of light emitting elements.
Abstract:
Methods of using a cycloheptathiophene compound for the treatment of xerophthalmia are described, as are formulations and compositions for such treatment.
Abstract:
A system and method for determining an operational status of a segment of a hybrid fiber coax (HFC) cable network. Subscriber premises units (SPUs) connected to the HFC cable network are “pinged” and their responses recorded. The two most responsive SPUs in each node of the HFC cable network are identified. The most responsive SPU is added to a primary ping list and the next most responsive SPU is added to a secondary ping list. The SPUs on the primary list are “pinged” and their responses recorded. If an SPU on the primary list fails to respond, the secondary SPU associated with the node is pinged. If both the primary and secondary SPU associated with a node fail to respond to the “ping,” the node is identified as non-responsive. If all of the nodes associated with a modulator (or a demodulator) are identified as non-responsive, the modulator (or demodulator) is identified as “non-responsive.” Additionally, network devices are pinged and their responses noted. Using the responsiveness of nodes and network devices, faults in segments in an HFC cable network can be identified and located.
Abstract:
A barrier movement operator controls movement of a movable barrier. The barrier movement operator includes a head unit, including a chassis, for commanding the movable barrier to perform movable barrier functions. A plurality of closely mounted light emitting elements are fixedly mounted onto the head unit. A heat sink is in thermal communication with the set of light emitting elements and with the chassis of the barrier movement operator to dissipate thermal energy from the set of light emitting elements. A controller is utilized for controlling the head unit to provide power to the set of light emitting elements.
Abstract:
An apparatus and method for delivering a plurality of medication includes providing first and second medicament on a medicament pack in separate containers for preventing either medicament from interfering with the stability of the other. In accordance with the method, the medicaments are preferably delivered in a single inhalation.
Abstract:
A control system for disabling the fan of a heating, ventilating, and air-conditioning system upon the detection of an audible alarm, such as a smoke alarm. The preferred embodiment utilizes a tunable band pass filter/decibel level detector in conjunction with a microphone to detect an audible alarm. When an alarm is detected, the fan is disabled whether the HVAC is operating in heating, cooling, or manual fan “on” mode.
Abstract:
A fault detection and isolation system for an HFC cable network and method therefore. A ping list generator captures set top box (STB) identifying information from a billing system, and STB state information from a network control system. The ping list generator creates a ping list from the STB identifying information and the STB state information, wherein the list comprises the IP address of a set of the addressable STBs connected to an HFC cable network. In an exemplary embodiment, the set is of sufficient size to be representative of the health of the HFC cable network. In another embodiment of the present invention, the set comprises substantially all of the addressable STBs connected to the HFC cable network. A ping generator, pings the IP address of the STB and awaits a response. If the response is received from the STB, then identify the STB as responsive. If the response is not received, then identify the STB as non-responsive. A fault isolation processor associates the STB identifying information and the ping response, determines whether a non-responsive fault indicator is present, and, if the fault indicator is present, then identifies a likely cause of the non-responsive fault.
Abstract:
The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers. The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.